Abstract: Elements of the nucleoside system (nucleoside levels, 5'-nucleotidases (5'NTs) and other nucleoside metabolic enzymes, nucleoside transporters and nucleoside receptors) are unevenly distributed in the brain, suggesting that nucleosides have region-specific functions in the human brain. Indeed, adenosine (Ado) and non-Ado nucleosides, such as guanosine (Guo), inosine (Ino) and uridine (Urd), modulate both physiological and pathophysiological processes in the brain, such as sleep, pain, memory, depression, schizophrenia, epilepsy, Huntington's disease, Alzheimer's disease and Parkinson's disease. Interactions have been demonstrated in the nucleoside system between nucleoside levels and the activities of nucleoside metabolic enzymes, nucleoside transporters and Ado receptors in the human brain. Alterations in the nucleoside system may induce pathological changes, resulting in central nervous system (CNS) diseases. Moreover, several CNS diseases such as epilepsy may be treated by modulation of the nucleoside system, which is best achieved by modulating 5'NTs, as 5'NTs exhibit numerous functions in the CNS, including intracellular and extracellular formation of nucleosides, termination of nucleoside triphosphate signaling, cell adhesion, synaptogenesis and cell proliferation. Thus, modulation of 5'NT activity may be a promising new therapeutic tool for treating several CNS diseases. The present article describes the regionally different activities of the nucleoside system, demonstrates the associations between these activities and 5'NT activity and discusses the therapeutic implications of these associations.
INTRODUCTION
Adenosine and non-Ado nucleosides, such as Guo, Ino and Urd, regulate neuronal and glial functions in the brain [1] [2] [3] [4] [5] [6] and participate in the modulation of different physiological (e.g., sleep and memory) and pathophysiological (e.g., epilepsy, Parkinson's disease and Alzheimer's disease) processes in the brain [2, 3, [7] [8] [9] [10] [11] [12] [13] . Thus, nucleoside derivatives, nucleoside uptake inhibitors and inhibitors of nucleoside metabolic enzymes have been used in drug development against various diseases, such as neurodegenerative disorders [9, 11, 14, 15] .
Elements of the nucleoside system are unevenly distributed in the brain and are dependent on age and gender [11, [16] [17] [18] [19] [20] [21] [22] . Interactions have been demonstrated in the nucleoside system, such as the interaction of local nucleoside levels with the activities of nucleoside metabolic enzymes and the distribution of Ado receptors in the human brain [20] as well as the interaction of A 1 Ado receptor (A 1 receptor) density with equilibrative nucleoside transporter (ENT; ENT1 subtype) density [23] and 5'NT levels [24, 25] . Alterations in the nucleoside system including the level, distribution and/or tors and their area-, age-and gender-dependence in the human brain; and (iii) the potential of the nucleoside system modulation in the development of pharmacological therapies with an emphasis on the relationships between 5'NTs and nucleoside levels, nucleoside transporters and nucleoside (Ado) receptors.
5'-NUCLEOTIDASES
5'-nucleotidases (5'-ribonucleotide phosphohydrolases, EC 3.1.3.5) catalyze the conversion of (deoxy)nucleoside monophosphates into (deoxy)nucleosides and inorganic phosphates via hydrolysis of a phosphoric ester bond [81, 82] . Intracellularly and extracellularly, 5'NTs, which are integrant components of the endo-and ectonucleotidase enzyme cascade, catalyze the final step of nucleotide dephosphorylation (from NMPs to its corresponding nucleosides) [56] [57] [58] [83] [84] [85] [86] . This process contributes to the maintenance of nucleoside/nucleotide levels and the balance necessary to ensure their physiological functions in the brain and modulates the nucleoside effects on brain tissue cells via nucleoside levels, nucleoside transporters and their receptors [82, 87] . In addition, the synaptic ectonucleotidase cascade system plays a role in the rapid termination of the activities of nucleoside di-and triphosphates on their receptors and in nucleoside recycling in the brain. Processes of nucleoside recycling consist of (i) intracellular synthesis of nucleoside triphosphates from nucleosides; (ii) release of nucleoside triphosphates into the extracellular space; (iii) extracellular degradation of nucleoside triphosphates into their corresponding nucleosides, which may exert their effects via nucleoside receptors (such as Ado receptors); and (iv) uptake of nucleosides into the cells, which contributes to the termination of nucleoside signaling via their receptors and the prompt re-utilization (salvage) of nucleosides. Consequently, intracellularly and extracellularly localized enzymatic chain reactions involving 5'NTs catalyzed reactions form a crosstalk between intracellular and extracellular nucleoside metabolism in the brain [56] [57] [58] [59] [88] [89] [90] .
Seven types of 5'NTs have been cloned, characterized [81, 91] and distinguished in cell extracts/micropunches using nucleotidase assays [92] [93] [94] . 5'-nucleotidases have been demonstrated in various tissues including brain tissue [81, 91, [95] [96] [97] [98] [99] . Five enzymes are cytoplasmic (cytosolic/soluble/cNs: cN-IA, cN-IB, cN-II, cN-III and cdN), one enzyme is mitochondrial (mdN) and one enzyme (e5'NT) is located on the outer side of the plasma membrane [81] . In this review article, we briefly discuss the main general features and role of 5'NTs. As (i) network of 5'NTs is complex (see the text below) and (ii) it is not clear whether results (derived from e.g., enzyme histochemistry) refer to only e5'NT, cNs or e5'NT plus cNs and so forth, it is sometimes impossible to ascribe an AMP hydrolyzing activity to a particular kind of 5'NT. Thus, when referring to generic 5'NTs in the text (and in the Table (1) without any further specification) we do not identify any specific 5'NT.
General Properties and Functions of 5'NTs
The ecto-5'-nucleotidase (aliases: e5'NT, CD73, ecto-5'-NT, eNT, NT5 and low K m -5'-NT) gene is located on chromosome 6q14-q21 [81, 100] . e5'NT is ubiquitously expressed and present on both neurons and glial cells. It contains two glycoprotein subunits (the molecular mass of the subunit is 60-80 kDa) and is anchored to the plasma membrane by a glycosylphosphatidyl-inositol molecule [81, 82, 101] . Furthermore, the existence of its soluble extracellular form has also been demonstrated [82, 86, 101, 102] . The substrate specificity of e5'NT is broad, as it can hydrolyze both ribo-and deoxyribonucleoside monophosphates. However, e5'NT exhibits the highest affinity for Ado monophosphate (AMP) (low K m -nucleotidase: K m for AMP is 1-50 M) [82, 86, [103] [104] [105] [106] . Its optimal pH is approximately 6.8-9.0 depending on the type of tissue [81, 82] . Both Mg 2+ and Mn 2+ increase the activity of e5'NT [82, 103, 105] , whereas Ado diphosphate (ADP) and Ado triphosphate (ATP) (and to a lesser extent Urd diphosphate/UDP, Urd triphosphate/UTP, Guo diphosphate/GDP, Guo triphosphate/GTP, cytidine (Cyd) diphosphate/CDP, Cyd triphosphate/CTP, concanavalin A and , -methyleneadenosine-5'-diphosphate (APCP)) inhibit e5'NT activity [82, 103, 105, 107] . Ecto-5'NT plays a role in (i) the extracellular generation of nucleosides [56] [57] [58] 86] and, as a consequence, nucleoside (e.g., Ado) receptor activation, neurotransmission modulation, and the regulation of learning and memory, sleep, psychomotor coordination, cardiac and renal function, platelet aggregation, nociception and so forth [7, 12, 82-84, 101, 108-116] ; (ii) the termination of nucleoside di-and triphosphates activity on their receptors [63, 82, 117, 118] ; (iii) the uptake of extracellular nucleosides [56] [57] [58] ; (iv) T-cell activation (as a coreceptor) [119] [120] [121] ; (v) cell-cell adhesion and cell proliferation [60, 62, 66, 121, 122] ; (vi) synaptic malleability/arrangements and information processing, neuroglial/cell-matrix interactions and synaptogenesis [61, [63] [64] [65] [66] [67] [68] 82] ; (vii) neuronal regeneration and development [67, 70, 82, 86, 101] ; (viii) the regulation of glial cell volume [123] ; and (ix) epithelial ion and fluid transport, adaptation to hypoxia, ischemic preconditioning, vasodilatation and inflammation [124] [125] [126] [127] .
The cytosolic 5'-nucleotidase IA (cN-IA, cN-I, AMPspecific 5'NT) and cytosolic 5'-nucleotidase IB (cN-IB, AIRP, cN-IA homologue: high homology between cN-IA and cN-IB was demonstrated) genes are located on chromosome 1p33-p34.3 and 2p24.3, respectively [96, 97] . Both cN-IA and cN-IB are ubiquitously expressed in human tissues [96, 97] , and their optimum pH is between 6.5 and 7.0 [81, 82] . Cytosolic 5'-nucleotidase IA exhibits a high affinity for (deoxy)nucleoside monophosphates, but its preferred substrate is AMP (K m 1.2-8.3 mM; cytosolic AMP specific 5'-nucleotidase, form A) [81, 82, 96, 128, 129] . This enzyme demonstrates a tetrameric structure (subunit molecular mass is 40-43 kDa) [81, 82, 129] and is activated by ADP and GTP [96, 128, 129] . Moreover, cN-IA is Mg 2+ dependent [96, 129] , does not show phosphotransferase activity [130] , and may be inhibited by 5-ethynyl-2',3'-dideoxyuridine [131] . This enzyme plays a role in the increase of Ado levels under ischemic and hypoxic conditions [132] and controls (together with cN-II) the intracellular level/pools of NMPs and nucleosides [57-59, 81, 96, 133] . Cytosolic 5'-nucleotidase IB catalyzes the hydrolysis of AMP (cytosolic AMP specific 5'-nucleotidase, form B), and it may be activated via ADP [97] . Furthermore, 5-ethynyl-2',3'-dideoxyuridine may inhibit not only cN-IA but also cN-IB [81, 131] .
Cytosolic 5'-nucleotidase II (cN-II, Ino monophosphate/IMP-Guo monophosphate/GMP specific NT, purine 5'NT, high K m 5'NT, IMPase), which is localized on chromosome 10q24.32 [81, 134] , is ubiquitously expressed in human tissues [81, 82, 135, 136] and has a tetrameric structure (the molecular mass of the subunit is 52-70 kDa) [82, [137] [138] [139] . Cytosolic 5'-nucleotidase II is Mg 2+ dependent [139] and prefers 6-hydroxypurine (deoxy)nucleoside monophosphates, such as IMP and GMP (IMP-GMP specific 5'-nucleotidase; K m for IMP is 0.1-0.6 mM) [82, 134, 139] . The optimal pH of cN-II is 6.0-7.0 [81, 82] . The activity of cN-II may be enhanced by (deoxy)ATP, GTP and ADP [82, [139] [140] [141] . Cytosolic 5'-nucleotidase II has a phosphotransferase activity from 6-hydroxypurine monophosphates (phosphate donors) to phosphate acceptors, such as Guo, (deoxy)Ino and nucleoside analogs, to form monophosphate derivatives [85, 133, [140] [141] [142] [143] , and plays a role in (i) purine nucleotide interconversion, (ii) the maintenance/modulation of intracellular 5-phosphoribosyl-1-pyrophosphate (PRPP) and purine nucleotide pools and (iii) the survival of cultured astrocytoma cells [81, 133, 144] .
The cytosolic 5'-nucleotidase III (cN-III, P5'-NT, P5'N-1, PN-I, UMPH, UMPH-I) gene is localized on chromosome 7p14.3 [81, 98, 143] . Cytosolic 5'-nucleotidase III is widely expressed in mouse, rat and human tissues [98, 145, 146] , is Mg 2+ dependent [147] , functions as a monomer (the molecular mass is 34 kDa) [98, 148] , and hydrolyzes pyrimidine monophosphates [147] . However, cN-III shows the highest affinity for Cyd monophosphate (CMP) (K m 10-150 M) [81, 91, 147] . The optimal pH for cN-III is 7.5, and the activity of cN-III may be inhibited by nucleosides (e.g., Urd), phosphates and heavy metals [147] . Similar to cN-II, cN-III demonstrates phosphotransferase activity, where it transfers a phosphate from pyrimidine monophosphates (phosphate donors) to Urd, Cyd and deoxycytidine (dCyd) (phosphate acceptors) [147] . It has been shown that cN-III is involved in the degradation of RNA during erythrocyte maturation [147, 148] and the catabolism of pyrimidine (deoxy)nucleosides [81, 148] . Genetic mutations (deficiencies) of cN-III in reticulocytes cause hemolytic anemia [147, 148] . Cytosolic 5'(3')-deoxyribonucleotidase (cdN, PN-II, dNT-1, UMPH-2) is widely distributed in human, mouse and rat tissues [99, 145, [149] [150] [151] . Its gene has been localized on chromosome 17q25 [151] . Cytosolic 5'(3')-deoxyribonucleotidase exhibits a dimeric structure (the molecular mass of the subunit is approximately 23 kDa) [148, 150] , is Mg 2+ dependent [150] , and prefers 2'-and 3'-monophosphates containing pyrimidine basis uracil (Ura) or thymine (Thy), such as 3'-deoxyuridine monophosphate (K m for 2'-and 3'-monophosphates is approximately 0.3 mM) [81, 150] . However, lower nucleotidase activities of cdN have also been demonstrated for 5'-deoxynucleotides (e.g., 5'-deoxyuridine monophosphate, 5'-dUMP) and 5'-ribonucleoside monophosphates (e.g., UMP) [92, 150] . Its optimal pH is between 5.5 and 7.5 [81, 149, 150] . Phosphate, deoxyinosine (dIno) and deoxyuridine (dUrd) may inhibit cdN activity, whereas deoxyguanosine monophosphate (dGMP) and deoxythymidine monophosphate (dTMP) may increase cdN activity depending on different substrate molecules [81, 150] . Human erythrocyte cdN exhibits phosphotransferase activity [91, 152] . Both PMcH-U ((±)-1-trans-(2-phosphonomethoxycyclohexyl)uracil) and PMcP-U ((±)-1-trans-(2-phosphonomethoxycyclopentyl) uracil) inhibit cdN activity [92, 153] . The physiological function of cdN may be involved in the regulation of pyrimidine (deoxy)nucleotide levels [148, 154] as well as nucleotide recycling in dying cells [81, 155] .
Genes of mitochondrial 5'(3')-deoxyribonucleotidase (mdN, dNT-2) are located on chromosome 17p11.2 [99, 151] . The expression of mdN has been demonstrated in mouse, rat and human tissues [99, 151, 156, 157] . It has a dimeric structure (the molecular mass of the subunit is 26 kDa) [99, 151, 157] and prefers pyrimidine monophosphates with Ura or Thy bases, such as 5'-dUMP (K m 0.1 mM) [81, 153, 157] . Mitochondrial 5'(3')-deoxyribonucleotidase is Mg 2+ dependent [157] and its pH optimum may be 5.0-5.5 [99, 153] .
inhibit mdN activity [92, 153] . In addition, mdN may be protective against excessive deoxythymidine triphosphate (dTTP) accumulation, which induces a mutagenic effect in mitochondrial DNA replication [91, 157] .
Anti-viral and anti-cancer nucleoside analogs (i.e., prodrugs) may be transported to the cells via nucleoside transporters and activated (as a triphosphate) via phosphorylation by kinases [81, 153, [158] [159] [160] . Triphosphorylated nucleoside analogs exert their therapeutic effects mainly by termination of DNA chains via inhibition of DNA polymerases and incorporation into DNA. Thus, increased activity of 5'NTs (mainly cNs and indirectly, e5'NT) [81, 158, 159] may inhibit the activation of nucleoside analogs by dephosphorylation, which results in drug resistance. Dephosphorylated nucleoside analogs are not able to terminate DNA chains and may be transported into the extracellular space from the cells [81, 159] . The involvement of cN-I and cN-II in drug resistance has been previously demonstrated. For example, the phosphorylated form of the anti-viral nucleoside analogue 3'-azido-2',3'-dideoxythymidine (AZT) is the substrate of these enzymes [81, 96, 147, 153] . Thus, development of new 5'NT inhibitors and nucleoside analogs, which are weakly metabolized by 5'NTs, may improve the therapeutic efficacy of some anti-viral and anti-cancer nucleoside analogs by decreasing resistance [81, 91] . Nevertheless, cN-II may also have a role in drug activation (e.g., the anti-viral nucleoside analog 2',3'-dideoxyinosine, ddI and AZT) via its phosphotransferase activity [81, 140, 161] . In addition, cN-III and cdN may be involved in nucleoside analog resistance (cN-III and cdN) and activation (cN-III), and mdN may reduce the toxic side effects of activated (phosphorylated) nucleoside analogs in mitochondria [81, 147] .
Structure-Activity Relationships
Considerable substrate specificity characterizes several 5´NTs. The preferred substrate is AMP for cN-I, IMP for cN-II, and pyrimidine nucleotides for cN-III. The phosphate moiety is present in all substrates and is important for its binding to the enzymes. Hydrolysis was dramatically reduced when modifications were introduced into the phosphate group. However, if the structure around the phosphor atom is not changed, but the oxygen connecting it with the ribose moiety is converted into a carbon, the resulting nonhydrolyzable phosphates represent promising antagonists of 5´NTs [162] . Consequently, the sugar moiety appears to be less important for substrate binding since its modifications affect the rate of hydrolysis to a lesser degree. Indeed, deoxynucleotides are also hydrolyzed by 5´NTs [163] , albeit with a much lower activity for e5'NT. The substrate specificity of 5´NTs is based on its recognition of the nucleobase. Not surprisingly, hydrogen-bond formation with the substituent in the 6-position of the purine ring and the hydrophobic attractions play major roles in the substrate specificity of 5´NTs [164] . The electron pair on N-1 is important in substrate binding of cN-II but is not a prerequisite for cN-I. However, hydrogen bonding with N-7 is not essential to substrate binding for either cN-I or cN-II [164] compared to Ado deaminase (ADA) [165] . Recent crystallographic approaches have provided a more detailed description of structure-activity relationships for 5´NTs. The structures of four of the seven human 5 NTs, cN-II, cN-III, mdN and e5'NT, have been previously described. Intracellular 5 NTs share three conserved motifs that have been identified in members of the haloacid dehalogenase superfamily of enzymes, suggesting divergent evolution from a common progenitor. The three motifs constitute the catalytic phosphate-binding site in these enzymes [166] . The first Asp in Motif I (DXDX[T/V]L) induces a nucleophilic attack on the phosphate of the NMP, and the second Asp donates a proton to the remaining nucleoside. This mechanism is thought to involve a stabilized pentacovalent phosphorane and a phosphoenzyme intermediate [167, 168] , suggesting phosphotransferase activity, which has been demonstrated in cN-II and cN-III [137] . In cN-III and mdN the active site is located in a cleft between two different domains [157] , in contrast, cN-II is a homotetrameric protein consisting of two identical dimers. The smallest active oligomerization state of the protein is dimer [137] . Unlike other 5 NTs, cN-II is allosterically activated by adenine/guanine nucleotides, which couple its activity to the metabolic state of the cell. This enzyme is also activated by millimolar concentrations of NaCl, KCl and LiCl, whereas inorganic phosphate demonstrated the opposite effect [137] . Activation of cN-II involved the transition of a catalytically essential Asp356. The substrate specificity of cN-II was determined by Arg202, Asp206 and Phe157 [169] . For cN-III, the structure and sequence analysis coupled with enzymatic characterization of several mutants revealed how cN-III achieved specificity for pyrimidine 5'NTs: the aromatic ring was stabilized by parallel pistacking interactions with Trp113 and His68 and by Tshaped stacking with Tyr114, as well as by polar contacts with side chains of Thr66 and Ser117. Two water molecules helped to stabilize the nucleotide binding by bridging it to protein residues Asp72 and His68 via hydrogen bonds [170] .
Interestingly, the eukaryotic e5'NT but not the cytosolic 5´NT is structurally related to bacterial 5'NT enzymes in terms of sequence similarity. Monomeric bacterial 5'NT enzymes consist of distinct N-terminal metal binding and Cterminal substrate-binding domains, which together form the active site [171, 172] . The N-and C-terminal domains undergo extensive domain rotations relative to each other and thereby switch between the open and closed structural conformations [173] . Ecto-5'-nucleotidase is a dimeric extracellular glycoprotein with similar open and closed conformations to bacterial enzymes [121] . A crystal structure of the closed and open formations of human e'5NT have been obtained [174, 175] . Structural control of the domain movement may be responsible for the selectivity of monophosphate nucleotides [176] .
REGIONAL DIFFERENCES AND CORRELATIONS IN THE NUCLEOSIDE SYSTEM OF THE HUMAN BRAIN
Age-and gender-modulated regional differences in the brain nucleoside system [11, 16-22] suggest (i) the existence of specific nucleoside pools in different brain areas, (ii) significant spatial differences in the nucleoside metabolic (anabolic and catabolic) network and signaling mechanisms induced by Ado and non-Ado nucleosides (i.e., Urd and Guo), (iii) fine and highly regulated modulation of different physiological processes in different human brain areas by nucleosides, (iv) the effect of nucleoside microenvironment on aging, which may be modulated by gender and (v) pathological consequences of changes in the nucleoside system, which may be related to the development of different CNS diseases, such as major depression, bipolar disorders, schizophrenia, Huntington's disease, Parkinson's disease and Alzheimer's disease as well as frontotemporal dementia [7, 50, [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] .
Nucleoside Metabolism and Nucleoside Levels
Ribonucleic acids (RNA) and deoxyribonucleic acids (DNA) consist of nucleotides that are synthesized from nucleosides and phosphate moieties. The major purine and pyrimidine ribonucleosides are Ado, Guo, Ino, and Cyd, Urd and thymidine (Thd) [187] , which contain purine or pyrimidine bases that are connected to a pentose moiety. Nucleosides are obtained from food and are partially synthesized de novo in the liver, which may be transported into the brain by nucleoside transporters and anabolized into their corresponding nucleotides intracellularly [56-58, 133, 188-190] . Since limited de novo synthesis of nucleosides has been observed in the adult brain [191] , salvage mechanisms have the predominant role in the preservation of purine and pyrimidine nucleosides and bases in the human brain ( Fig.  (1) ). Hypoxanthine phosphoribosyltransferase (HGPRT; hypoxanthine-guanine phosphoribosyltransferase), Ado kinase (ADK), adenine (Ade) phosphoribosyltransferase (APRT), Cyd deaminase (CDA) and Urd-Cyd kinase (UCK) catalyze the conversion of (i) hypoxanthine (Hyp) to IMP and guanine (Gn) to GMP, (ii) Ado to AMP, (iii) Ade to AMP and (iv) Cyd and Urd to CMP and Urd monophosphate (UMP), respectively ( Fig. (1) ) [56-58, 189, 192-194] . The intracellular degradation of ATP and ADP by nucleoside triand diphosphate phosphatases followed by the catabolism of AMP occurs via two degradation pathways: AMP to IMPIno-Hyp (IMP pathway) or to Ado-Ino-Hyp (Ado pathway) ( Fig. (1) ) by AMP deaminase (AMPDA), cNs (cN-I and cN-II, the rate-limiting enzymes of intracellular Ado formation), ADA and purine nucleoside phosphorylase (PNP). Adenosine is also synthesized from S-adenosylhomocysteine (SAH) by adenosylhomocysteinase (SAHH, Sadenosylhomocysteine hydrolase) (Fig. (1) ). The steady-state concentration of Ado is maintained by the simultaneously active cNs, ADK and ADA [56, 58, 195] ; thus, an alteration Abbreviations: cN: cytoplasmic 5'-nucleotidases; ADA: adenosine deaminase; Ade: adenine; ADK: adenosine kinase; Ado: adenosine; AMP: adenosine monophosphate; AMPDA: AMP deaminase; APRT: adenine phosphoribosyltransferase; ASL: adenylosuccinate lyase; ASS: adenylosuccinate synthetase; ATP: adenosine triphosphate; BBB: blood brain barrier; CDA: cytidine deaminase; CMP: cytidine monophosphate; CTP: cytidine triphosphate; Cyd: cytidine; DHT: dihydrothymine; DHU: dihydrouracil; DPD: dihydropyrimidine dehydrogenase; dThd: deoxythymidine; dTMP: deoxythymidine monophosphate; dTTP: deoxythymidine triphosphate; dUMP: deoxyuridine monophosphate; e5'NT: ecto-5'-nucleotidase; eNSp: ecto-nucleoside pyrophosphatase diphosphohydrolase; eNTPd: ecto-NTP diphosphohydrolase; GDA: guanine deaminase; GMP: guanosine monophosphate; GMPR: GMP reductase; GMPS: GMP synthetase; Gn: guanine; G s/i/q/olf : G proteins; GTP: guanosine triphosphate; Guo: guanosine; Hcy: homocysteine; HGPRT: hypoxanthine phosphoribosyltransferase (hypoxanthine-guanine phosphoribosyltransferase); Hyp: hypoxanthine; IMP: inosine monophosphate; IMPDH: IMP dehydrogenase; Ino: inosine; MTA: 5'-deoxy-5'-methylthioadenosine; MTAP: 5'-deoxy-5'-methylthioadenosine phosphorylase; NDPs: nucleoside diphosphates; NMPs: nucleoside monophosphates; NRs: nucleoside receptors; NSr: nucleoside release (via nucleoside transporters); NSs: nucleosides; NTPs: nucleoside triphosphates; NTr: nucleotide release (via e.g. ATP channels and transporters as well as synaptic release); PNP: purine nucleoside phosphorylase; RNR: ribonucleotide reductase; SAH: S-adenosylhomocysteine; SAHH: adenosylhomocysteinase; S-AMP: adenylosuccinate; Thy: thymine; TK: thymidine kinase; TP: thymidine phosphorylase; TS: thymidylate synthetase; UA: uric acid; UCK: uridine-cytidine kinase; UDP: uridine diphosphate; UMP: uridine monophosphate; UP: uridine phosphorylase; Ura: uracil; Urd: uridine; UTP: uridine triphosphate; Xao: xanthosine; XMP: xanthosine monophosphate; Xn: xanthine; XO: xanthine oxidase; we didn't show intracellular nucleoside mono-and diphosphate kinases or nucleoside di-and triphosphate phosphatases.
in these enzymes' activity may change Ado levels and the effects of Ado on brain cells. Guanine-ribonucleotides may degrade via two pathways in the brain: the GMP-Guo-Gnxanthine (Xn) pathway, which is catalyzed via cN-II, PNP and Gn deaminase (GDA) (Fig. (1) ); or the GMP-IMP-InoHyp-Xn pathway, which is regulated by GMP reductase (GMPR), cN-II, PNP and Xn oxidase (XO). Since uricase enzyme activity has disappeared from the mammalian brain during evolution, the final step of purine catabolism is the conversion of Xn into uric acid (UA) by XO in the human brain [95, 188, 196] .
Extracellular nucleoside triphosphates (ecto-NTPs) may degrade into nucleoside diphosphates (NDPs), NMPs and nucleosides via an ectonucleotidase cascade system involving ecto-NTP diphosphohydrolases (eNTPd), ectonucleoside pyrophosphatase diphosphohydrolase (eNSp) and e5'NT ( Fig. (1) ) [56, [83] [84] [85] [86] 197] . The extracellular levels of Ado are formed extracellularly from ATP and released from cells that are regulated by e5'NT, ecto-adenosine kinase (ecto-ADK) and ecto-adenosine deaminase (ecto-ADA) [56, 86, 101, [198] [199] [200] [201] [202] .
Similarly to purine nucleotides, pyrimidine nucleotides (UTP; CTP; Thd triphosphate, TTP) are also intracellularly metabolized into their di-and monophosphate derivatives as well as nucleosides (Urd, Cyd and Thd) by nucleoside triand diphosphate phosphatases and cNs. The end products of pyrimidine nucleotide metabolism are dihydrothymine (DHT) and dihydrouracil (DHU) (Fig. (1) ). Degradation of extracellular pyrimidine nucleotides into their corresponding nucleosides is catalyzed by eNTPd, eNSp and e5'NT [22, 56, 57, 189] .
Several nucleoside metabolic enzymes, such as 5'NT, ADA, ADK, PNP and GDA, are unevenly distributed in the human brain [22, [203] [204] [205] [206] [207] (Table 1) . High activities of 5'NT, ADA, ADK, PNP and GDA have been previously demonstrated in several human brain areas (e.g., thalamus, hypothalamus and amygdala), whereas low levels have been detected in other brain areas (e.g., cerebellum and medulla oblongata). Most human brain areas demonstrate intermediate activity of 5'NT (e.g., parietal lobe, cingulate cortex, insula, caudate nucleus, putamen, pallidum (internal), thalamus (anterior), subthalamic nucleus, nucleus ruber, substantia nigra, amygdala and hypothalamus), ADA (e.g., gray matter of the frontal, occipital, orbital, parietal and temporal lobes; pons; putamen; hippocampus; caudate nucleus; globus pallidus; thalamus; and midbrain), ADK (e.g., cerebellum, temporal cortex and occipital cortex), PNP (e.g., caudate nucleus, medulla oblongata, white matter of the frontal lobe and gray matter of the temporal, parietal and frontal lobes) and GDA (e.g., parietal cortex, caudate nucleus, putamen, hippocampus and substantia nigra) ( Table 1) . These results indicate spatial differences in the complex nucleoside metabolic network in relation to their functions in the CNS. Volonté and Ambrosi [53] have proposed that several elements of the purinergic (and likely the pyrimidinergic) system are tightly integrated with each other and modulate neuronal function together. For example, changes in one or more ele- ments of the nucleoside system may result in an alteration(s) in its function. An increase or decrease in the extracellular and intracellular concentration of nucleosides may also change nucleoside uptake via their transporters and thereby alter nucleoside function via nucleoside receptors in the brain. Thus, regionality in nucleoside metabolic enzyme activity in different human brain areas, and their changes may reflect different roles of these enzymes in physiological functions and may cause pathophysiological processes in the brain.
It has been revealed that nucleoside concentrations are unevenly distributed in different human brain areas and that they may be age and gender dependent [16, [20] [21] [22] . On the basis of the extrapolation method [19] , Kovács and colleagues prepared the first [57] nucleoside map of the human brain [20] . High Ado and/or Ino, Guo and Urd levels were calculated in the cochlear nuclei, vestibular nuclei, temporal and occipital cortices, cerebellar cortex, caudate nucleus and nucleus basalis ( Table 2) , and the lowest concentrations were measured in the entorhinal cortex, zona incerta, substantia nigra, locus coeruleus, and habenula, among others ( Table  2) . The highest and lowest nucleoside levels were measured in the cochlear nuclei and zona incerta, respectively. Moreover, both the nucleosides and their metabolites (e.g., Hyp, Xn and Ura) were unevenly distributed in the human brain [20] .
Levels of Ino and Ado increased with age in the human frontal cortex, whereas lower Ado levels and higher Urd, Ino and Guo concentrations were measured in middle-aged and/or elderly female cortical samples when compared to middle-aged and older males [21] . Taken together, these findings indicated that (i) increased levels of Ado may result from increased activity of 5'NTs (mainly e5'NT and/or cN-I) according to age and that (ii) different human brain 5'NTs activities may exist between females and males, consistent with findings obtained from previous animal studies [118, [208] [209] [210] [211] [212] [213] . These results suggested that (i) age and gender may modulate nucleoside levels and nucleoside metabolic enzymes activities and that (ii) the nucleosides may have a role in aging processes in the brain and in decreasing the effects of excitotoxic insults on the female brain [21].
Nucleoside Transporters
Nucleoside transporters control the levels of nucleosides required to maintain the nucleoside balance in the extracellular and intracellular space and to exert their functions in brain tissue. Nucleosides are transported via the membranes of brain cells by two types of nucleoside transporters [15, 54, 214] . The ENT family consists of four ENT transporter types (ENT1-ENT4), which achieve bidirectional facilitated (equilibrative) diffusion depending on extracellular/intracellular concentration gradient [15, 56] . Equilibrative S-(4-nitrobenzyl)-6-thioinosine (NBTI)-insensitive ENT types ('ei'; e.g., ENT2) are inhibited by M concentrations of NBTI, whereas NBTI-sensitive ENT types ('es'; e.g., ENT1) are inhibited by three orders of magnitude lower levels (nM concentration) of NBTI. Different types of ENT transporters can transport purines and pyrimidines (e.g., ENT1-ENT3) and their bases (e.g., ENT2 and ENT3). The concentrative nucleoside transporter (CNT) family consists of six CNT transporter types (N1-N6), which transport nucleosides unidirectionally and in a sodium/proton-dependent manner (symport of sodium ions or sodium ions and protons with nucleosides into the cells) in the brain. Concentrative nucleoside transporters are classified on the basis of their transported nucleosides (e.g., CNT3 transports purines and pyrimidines, whereas CNT1 transports pyrimidines, Ino and Ado) and sodium/proton transport coupling [15, 23, [215] [216] [217] [218] . Nucleoside analogs with anti-viral and anti-tumor effects are transported via both ENT and CNT transporters [160, 214] .
The uneven distribution of nucleoside transporters has also been demonstrated in the human brain [23, [215] [216] [217] [218] , which showed different expression patterns of ENT1-ENT4 transporters (e.g., high ENT1, intermediate ENT3 and low ENT2 and ENT4 transporter density was demonstrated in the frontal cortex) with the exception of the thalamus, where ENT transporters are expressed at uniformly intermediate levels ( Table 3 ). The distribution of CNT1 transporters was uniform, but the expression of CNT2 and CNT3 transporters were uneven in the human brain ( Table 3) . Relatively high expression of CNT2 and CNT3 transporters was demonstrated in the cerebellum, putamen, hippocampus, medulla oblongata and pituitary gland, whereas intermediate/low activities were demonstrated in other brain areas, including the amygdala; frontal, occipital and temporal lobe; substantia nigra; thalamus; spinal cord; cerebellum; caudate nucleus; putamen; and nucleus accumbens ( Table 3) . This uneven distribution of nucleoside transporters may reflect the different roles of nucleoside transporter types in neuromodulation at functionally different brain areas [23, [215] [216] [217] [218] . receptors has been demonstrated in several human brain areas (e.g., in the parietal, temporal and occipital cortices, caudate nucleus; putamen; globus pallidus; nucleus accumbens; and hippocampus), whereas other brain areas showed intermediate or low expression of A 1 , A 2A and A 3 receptors (e.g., in the frontal cortex, thalamus, medulla oblongata, midbrain and pons). A 2B receptors are uniformly distributed in the human brain (Table 4) .
Nucleoside Receptors
Age-related changes in Ado receptor distribution have been shown in the brains of both animals and humans. Since A 1 receptor density was decreased and A 2A receptor activity was increased by age, the excitatory(A 2A )/inhibitory(A 1 ) effects/balance may also shift toward excitation via A 2A receptors with aging [182, [233] [234] [235] [236] [237] [238] [239] [240] . Consequently, increased Ado levels in the aged human brain may increase the release of neurotransmitters, which may have both positive (e.g., increasing acetylcholine release in dementia) and negative (e.g., increasing the risk of excitotoxicity) effects [12, 118, 241, 242] .
Correlations Between Elements of the Nucleoside System
Interactions have been demonstrated between (i) regional differences in the nucleoside concentrations and the distribution of nucleoside metabolic enzyme activities and Ado receptor expression [20] , (ii) NBTI binding site and the density of ADA immunoreactive neurons [243] , (iii) ENT1 transporters and A 1 receptor density [23], (iv) 5'NT levels and A 1 receptor density [24, 25] and (v) ADA and A 1 receptor functionality [201] in the nucleoside system. In contrast, the distribution of ENT2 transporters has not shown a correlation with either A 1 or A 2A receptor density in the human brain [23] . In this review, we discuss the association of 5'NTs with nucleoside levels, nucleoside transporters and Ado receptors.
The nucleoside metabolic enzyme activity may be related to the uneven distribution of nucleosides in the human brain [20, [203] [204] [205] [206] [207] (Table 1 and 2) . Intermediate or high 5'NT activity and/or low or intermediate ADA/ADK activity may increase the concentration of Ado, Ino, Guo and Urd Functional relationships were revealed between different elements of the nucleoside system and its function under physiological and pathophysiological (e.g., hypoxic/ischemic) conditions. Intracellular levels of nucleoside triphosphates (NTPs) were approximately 0.2-10.0 mM, whereas the concentrations of the nucleosides were at least three orders of magnitude lower in the human brain. Thus, a small decrease in NTPs levels and/or changes in enzymatic activity of the nucleotide/nucleoside metabolic systems may cause a dramatic alteration in the nucleoside levels [20, [250] [251] [252] [253] [254] [255] . Extracellular nucleoside triphosphates (such as ATP and UTP) competitively inhibit the activity of e5'NTs, causing a delay in the onset of nucleoside production [58, 118, [256] [257] [258] . Thus, the increased extracellular nucleotide levels (e.g., ATP) in the synaptic cleft (e.g., under hypoxic/ischemic conditions) may cause an accumulation of NMPs (e.g., AMP) to a greater extent compared to nucleosides (e.g., Ado). The decrease in nucleoside triphosphate levels may result in relief of e5'NT inhibition and thereby elevate nucleoside levels and nucleoside transport into the brain cells anabolized into nucleoside mono-, di-and triphosphates derivatives [58, 84, 85, 257] . During normoxic conditions (at 3.6 mM ATP levels) [133] , extracellular nucleotides (e.g., ATP) are mainly catabolized into nucleosides (e.g., Ado) since the level of e5'NT inhibitor nucleoside triphosphates are lower than under ischemic conditions. Under these conditions, intracellular ATP is catabolized into Ino via IMP (IMP pathway; AMPDA and cN-II may be activated by ATP) rather than into Ado, which maintained low cytoplasmic Ado levels [57] . Decreased levels of intracellular ATP under ischemic conditions (less than 2 mM ATP levels) [59] may slow down the nucleoside recycling system [88, 133] . In addition, AMP is also degraded into Ino, but it is degraded via the Ado pathway since the degradation of ATP decreases the activation of AMPDA and cN-II [57, 59, 133] (Fig. (1) ). In addition, under these circumstances, the K m value for IMP increases from micromolar to millimolar [140] . As a consequence of the increased Ado levels, Ado may be released into the extracellular space via ENT transporters and contribute to the protection of brain tissue cells via A 1 /A 2 receptor activation (e.g., reduction of ischemic injury by vasodilatation and inhibition of glutamate release) [1, 13, 79, 118, [259] [260] [261] [262] .
A tight interplay between extracellular ATP metabolism (involving AMP catabolism by e5'NT), activation/inhibition of Ado receptors and function of nucleoside transporters and nucleotide/neurotransmitter release has also been demonstrated in rat hippocampal glutamatergic nerve terminals [115, 263] . Low frequency nerve stimulation may cause the release of a small amount of ATP into the synaptic cleft, thereby resulting in low extracellular concentrations of Ado from the degradation of ATP via the ectonucleotidase cascade system and the release of Ado via ENT transporters. Subsequently, Ado may decrease neurotransmitter (and ATP) release via the activation of A 1 receptors [115, 264] . The greater activation of A 1 receptors compared to A 2A receptors by Ado (derived mainly via nucleoside transporters) may be associated with the tight proximity of A 1 receptors and nucleoside transporters in synapses [115, 263] . Indeed, the human ENT1 transporter distribution correlated with the density of A 1 receptors in the brain [23, 265] , which also strengthened the correlation between human ENT1 transporter-mediated transport processes and A 1 receptormediated neuromodulation [23] . However, high frequency stimulation also increased the amount of ATP released from the cells, which enhanced the extracellular levels of Ado via ectonucleotidases resulting in (i) a stronger activation of A 2A receptors compared to A 1 receptors and (ii) an A 2A receptorevoked increase of neurotransmitter and ATP release as well as ENT transporter uptake activity [115, 263, 266] . Increased activation of A 2A receptors by high Ado levels (derived from extracellular ATP metabolism) may be due to the close proximity of A 2A receptors and e5'NT, whereas decreased activation of A 1 receptors may be due to limited Ado availability to A 1 receptors via suppression of Ado spreading in synapses by the A 2A receptor-evoked increase in Ado uptake [115, 263] .
An increase in the expression and/or synthesis and activity of e5'NT may enhance neuromodulation by increasing Ado levels via Ado receptors [1, 267, 268] . Thus, the e5'NT activity may be functionally coupled with an activation of Ado receptors [81] 1 and 4) .
Although the Ado uptake inhibitor dipyridamole showed no effect on the activity of e5'NT and e5'NT inhibition by anti-5'-nucleotidase IgG did not evoke an alteration in the Ado uptake into astrocytes [258] , there may be a relationship between e5'NT activity and Ado transporters [270] [271] [272] . A close association between e5'NT and nucleoside transporters was demonstrated in vascular endothelial cells, heart cells and other cell types [270, 273] , which indicated vectorial transport of Ado via nucleoside transporters [258, 271] . Transport of Ado from AMP by e5'NT into the cells was more rapid compared to Ado in free solution. Consequently, e5'NT-catalyzed hydrolysis of AMP may contribute to Ado uptake [270, 271] . Taken together, e5'NT may function as an integral part of the nucleoside transport process [270, 271] , and activity of e5'NT may be linked to Ado translocation in brain cells. Indeed, the ectonucleotidase system and nucleoside transporters may form a cycle for the control of vascular tone in vascular cells (release of ATP, ATP catabolism to Ado, termination of Ado action/vasodilatation by the uptake of Ado) after hypoxia [273] . High 5'NT activity may be attributed to intermediate ENT1 and high ENT3 and ENT4 expression in the human temporal cortex, whereas enhanced 5'NT activity in the thalamus showed intermediate ENT transporter (ENT1-ENT4) activity [23, 204, 215, 216] (Table  1 and 3) . Importantly, the cerebellum exhibited low 5'NT activity and low ENT1, ENT3 and ENT4 density but high ENT2 density, which indicates the main nucleoside transporter type(s) differs among functionally different human brain areas.
Modulatory effects of 5'NTs on the purinergic/nucleosidergic system and their physiological/pathophysiological effects are dependent not only on their distribution/activity in the brain, but also on (i) the availability, proximity and distribution of nucleosides, nucleoside transporters and nucleoside receptors in different brain areas and (ii) on relationships between nucleoside system elements. However, alterations not only in the nucleoside levels but also in other elements of the nucleoside system, which may modulate nucleoside functionality, such as 5'NTs, may affect the physiological roles (e.g., cognition and memory, motor control, emotions, sensory information processing) of nucleosides [12, 265, [274] [275] [276] [277] [278] and cause pathophysiological conditions and diseases (e.g., Alzheimer's disease, Parkinson's disease and Huntington's disease) [12, 279] in the human CNS.
CONCLUSIONS: THERAPEUTIC TOOLS AND PERSPECTIVES

Therapeutic Tools Against CNS Diseases Based on the Nucleoside System
Drugs that modulate the nucleoside system are widely used, for example, (i) as anti-cancer and anti-viral therapies and treatment for gout (e.g., nucleoside metabolic enzyme inhibitors and/or synthetic nucleosides), (ii) as coronary vasodilators (e.g., nucleoside transport inhibitors), (iii) as vasodilators, and (iv) to treat cardiac arrhythmias, acute renal failure, carcinomas, rheumatoid arthritis and asthma (e.g., Ado receptor agonists and antagonists) [11, 13, 15, 38, 54, 158, [280] [281] [282] [283] [284] [285] [286] . Modulation of the adenosinergic system is also effective against several brain disorders, such as multiple sclerosis [287, 288] , in which specifically affected brain regions are not known. Thus, the identification of brain regions in which changes in one or more elements of the nucleoside system may be associated with these diseases is likely impracticable. However, considering the regionally different physiological roles of nucleosides in the brain, regional differences in the nucleoside system and its changes in affected brain areas may be related to the development of CNS diseases as previously discussed [11] . Moreover, regional differences were demonstrated in the nucleoside system of human brain areas implicated in several CNS diseases in which different drugs effects on the nucleoside system are or may be used later in treatment of the following CNS diseases ( [186, 317, 318] . In addition, Urd and/or Guo and Ino may also have therapeutic potential against epilepsy, pain, anxiety, schizophrenia, sleep disorders, ischemic injury, multiple sclerosis, Alzheimer's disease and Parkinson's disease, among others [3, 6, 79, [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] . Thus, elements of the nucleoside system are promising drug targets for the treatment of brain disorders, such as epilepsy, schizophrenia, Alzheimer's, Huntington's and Parkinson's diseases. However, mechanisms underlying the regional differences in the nucleoside system in specific areas of the human brain implicated in CNS diseases have not yet been elucidated (e.g., thalamic relay nuclei, periaqueductal gray, rostroventromedial medulla, and thalamic reticular and relay nuclei, tuberomamillary nucleus, and so forth, are involved in the physiological processes of pain and sleep). Thus, (i) to reveal the precise links between the regional differences of the nucleoside system, which are modulated by age and gender, and brain diseases, (ii) to obtain evidence that changes in the nucleoside system are a consequence of mechanisms underlying brain diseases and (iii) to develop effective and safe therapeutic strategies against brain diseases based on the nucleoside system, future studies on the nucleoside system focused on all of the affected human brain areas are required.
Modulation of 5'-Nucleotidase Activity: A New Promising Therapeutic Tool for the Treatment of Several CNS Diseases
Since e5'NT-generated nucleoside levels may be sufficient to exert modulatory effects via stimulation of their receptors and provide nucleoside uptake into the cells, an alteration of e5'NT activity may be involved in the progression of disorders in the brain and, as a consequence, modulation of e5'NT activity may be a potential target for the development of drugs effective against several CNS diseases.
It has been demonstrated that the activities of 5'NTs are altered under different pathological conditions. Increased cN-II (in Lesch-Nyhan patients with HGPRT deficiency) and Abbreviations: A1 receptor/A2A receptor/A2B receptor/A3 receptor: A1/A2A/A2B/A3 subtype of adenosine receptors; ADA: adenosine deaminase; ADK: adenosine kinase; Ado: adenosine; CNT transporters: concentrative nucleoside transporters; ENT transporters: equilibrative nucleoside transporters; GDA: guanine deaminase; Guo: guanosine; Ino: inosine; PNP: purine nucleoside phosphorylase; Urd: uridine; XO: xanthine oxidase e5'NT (in nucleotidase-associated pervasive developmental disorders) activity are associated with neurological symptoms, such as seizures and ataxia [35, 37, 38, 87, [336] [337] [338] . Increased serum 5'NT (enhanced AMP hydrolysis by e.g., glycosylphosphatidyl-inositol anchored and mainly soluble extracellular form of e5'NT) [82, 200] activity have also been shown in a chronic animal model of electroconvulsive shock [339] , in patients with epilepsy and in clozapinetreated schizophrenic patients [72, 73] and in pentylenetetrazol-induced seizures [74, 75] . Moreover, increased e5'NT activity has also been demonstrated in the rat striatum after chronic clozapine treatment [340] , in different rat models of epilepsy evoked by administration of pentylenetetrazol, kainic acid and pilocarpine [76] [77] [78] and in a rat model of Parkinson's disease [71] . Furthermore, 3-mercaptopropionic acid induced seizures, which increased e5'NT activity in the rat cerebellum [341] . The hippocampus of temporal lobe epileptic patients also showed enhanced e5'NT activity [68] . In addition, the pilocarpine-induced increase in e5'NT activity may be prevented by anti-epileptic drugs (phenytoin, carbamazepine) [342] . These results suggest that e5'NT may play a role in (i) sprouting control, (ii) the modulation of epileptic activity and (iii) blockade of spontaneous seizures by the production of the inhibitory neuromodulator Ado [72, 77, 343] and (iv) reactive synaptogenesis in temporal lobe epileptic patients [68] . Focal ischemia also increased the activ-ity of cerebroprotective e5'NT, which may increase the levels of neuroprotective Ado [63, 118, 126, 344, 345] . Rosuvastatin increased the extracellular levels of Ado via an enhancement of e5'NT activity and, as a consequence, increased the vasodilatator response to ischemia [346] . Upregulation of e5'NT activity was also demonstrated in models of brain damage, such as the cortical stub injury [347, 348] . Thus, increased activity of e5'NT after brain injury, epilepsy and other conditions may be an adaptive response that increases the levels of extracellular Ado and enhances its neuroprotective/anti-epileptic/anti-epileptogenetic effects via A 1 receptors [1, 13, 79, 349] . In addition, modulation of e5'NT activity (e.g., by activators of e5'NT such as methotrexate) [350] may be a potential treatment used to improve cognitive and motor deficits, chronic inflammation associated with neurodegenerative diseases [114, 351] , and febrile illness [352] via A 1 receptors. Moreover, interferon-(IFN-) upregulated e5'NT expression, which may have a role in the beneficial effects of IFN-treatment in patients with multiple sclerosis via increased Ado levels-evoked enhancement of endothelial barrier function, suggesting the important neuromodulatory role of e5'NT in brain inflammation [126, [353] [354] [355] . However, both Ado and non-Ado nucleosides (such as Urd and Guo) continuously form intraand extracellularly from corresponding triphosphates and are recycled/transported by nucleoside transporters [57, 59, 88] , which exhibit anti-epileptic/neuroprotective effects [39, 322, 325, [356] [357] [358] . For example, activity of the ectonucleotidase cascade system increased after quinolinic acid-evoked seizures in rat hippocampal slices [359] . Both Guo and GMP via metabolism to Guo by e5'NT showed anti-convulsant effects in rats [360] . In addition, pentylenetetrazol kindling increased GMP hydrolysis in the rat hippocampus [78] . Furthermore, recombinant e5'NT exerted anti-nociceptive effects in mice via the hydrolysis of AMP and A 1 receptor activation [361] . Thus, application of recombinant e5'NT may be a therapeutic tool used to treat chronic pain [109, 300, 361, 362] and may likely serve as a treatment approach in several other CNS diseases in which increased levels of Ado may have beneficial effects, such as epilepsy. Consequently, elucidation of the precise role of 5'NTs and changes in its activity in the pathomechanism of brain disease may provide an opportunity for the application of 5'NT modulation as a promising therapeutic tool against several CNS diseases.
Inhibitors of e5'NT, such as APCP, 3,3 ,4 ,5,7-pentahydroxyflavon (quercetin), 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0952), sodium nitroprusside (SNP), and 1-amino-4-[2-anthracenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0963) as well as anti-CD73 antibodies may potentially treat several diseases in the CNS [62, 124, 144, 254, 280, [363] [364] [365] [366] [367] [368] . Indeed, APCP and quercetin reduced the proliferation of human glioma cells (U138MG cell line) by inhibition of e5'NT activity and, as a consequence, decreased the extracellular levels of the glioma cell proliferation/adhesion stimulator Ado [62, 367, 369, 370] . Decreasing e5'NT activity may also serve as a promising therapeutic target in melanoma, which could be metastatic to the brain [371] . In addition, inhibition of overexpressed cN-II may increase the cytotoxic effects of anti-viral and anti-cancer nucleoside analogs [159, 372] . However, APCP also showed convulsant effects in rats [373] , and decreased activity of 5'NTs was demonstrated in brain sample homogenates obtained from patients with Alzheimer's disease [374] . These results suggest that the therapeutic application of 5'NTs inhibitors may be limited due to a reduction in the neuroprotective/anti-epileptic effects of nucleosides, such as Ado, Urd and Guo.
Taken together, the available data suggest that application of drugs effective on nucleoside metabolic enzymes, such as 5'NTs, nucleoside transporters and Ado receptors (Table 5) , may represent effective and safe therapeutic approaches against different CNS diseases via the reestablishment of the fine regulation of different physiological functions by the nucleosidergic system, which may be altered under pathological conditions in the human brain. Further studies are required (i) to understand the links between unevenly distributed nucleoside levels and the distribution of nucleoside metabolic enzymes activity, nucleoside transporters and Ado receptors under physiological conditions in the human brain, (ii) to reveal changes in the nucleoside system induced by different diseases in affected human brain areas, (iii) to obtain evidence for the precise role of different elements of the nucleoside system in the progression of human CNS diseases and (iv) to develop useful and safe pharmacological strategies based on the nucleoside system without (or with minimal) side effects against CNS diseases. To achieve this goal, the generation and comparison of functional anatomical brain maps of the nucleoside system containing information on (i) extracellular nucleoside levels, (ii) intracellular/tissue nucleoside levels, (iii) activity of intracellular nucleoside metabolic enzymes, (iv) activity of enzymes in ectonucleotidase cascade system, (v) expression of nucleoside transporters and (vi) nucleoside receptor density based on standard research/methodological conditions and simultaneous measurement of the same (age, gender, cause of death, etc.) samples from brain areas implicated in different brain diseases are required not only in healthy and diseased human brains but also in experimental animal models of different human CNS diseases.
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